FDA Drug Labeling, Approval Process Help Minimize Lawsuits Against Pharmaceutical Companies

Bruce N. Cronstein, MD, received his training at NYU School of Medicine. Currently a member of the ACR Board of Directors, Dr. Cronstein directs the NYU-H+H Clinical and Translational Science Institute at NYU School of Medicine.

Reference

1. McGinley L. The head of the FDA defends the importance of drug effectiveness. 2016 Dec 29. The Washingon Post.

Disclosures: Dr. Cronstein has acted as a consultant for Bristol-Myers Squibb and AstraZeneca; he has received grants from AstraZeneca, Celgene and Takeda and has equity in Can-Fite Biopharma. Dr. Cronstein’s research has been supported by the NIH (ROl AR056672-07, ROl AR068593-02, 1UL1TR001445-02), Arthritis Foundation and Celgene. Dr. Cronstein is the holder of multiple patents.